Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) EBIT: 2020-2024

Historic EBIT for Prime Medicine (PRME) over the last 5 years, with Dec 2024 value amounting to -$202.5 million.

  • Prime Medicine's EBIT rose 0.48% to -$54.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$204.0 million, marking a year-over-year increase of 9.87%. This contributed to the annual value of -$202.5 million for FY2024, which is 1.14% up from last year.
  • Prime Medicine's EBIT amounted to -$202.5 million in FY2024, which was up 1.14% from -$204.8 million recorded in FY2023.
  • Prime Medicine's EBIT's 5-year high stood at -$932,000 during FY2020, with a 5-year trough of -$204.8 million in FY2023.
  • Over the past 3 years, Prime Medicine's median EBIT value was -$202.5 million (recorded in 2024), while the average stood at -$174.6 million.
  • Per our database at Business Quant, Prime Medicine's EBIT tumbled by 8,963.73% in 2021 and then rose by 1.14% in 2024.
  • Prime Medicine's EBIT (Yearly) stood at -$932,000 in 2020, then plummeted by 8,963.73% to -$84.5 million in 2021, then crashed by 37.96% to -$116.5 million in 2022, then tumbled by 75.72% to -$204.8 million in 2023, then climbed by 1.14% to -$202.5 million in 2024.